CINCINNATI, OH, USA (July 11, 2017) — M Pharmaceutical Inc. (CSE: MQ, OTCQB: MPHMF, FWB: T3F2), (the “Company” or “M Pharma”), a clinical-stage company developing innovative technologies for weight management and female health and wellness announced today that it has taken important steps to release the innovative, FDA-cleared OTC product, ToConceive, to the North American marketplace. The Company acquired the global marketing rights to ToConceive in November of 2016 and immediately contracted with Anstice Communications (Anstice) based in Calgary. Anstice, one of Canada’s leading integrated communications agencies, has developed new branding, packaging and website for ToConceive and is assisting in driving information and awareness about ToConceive to the public in advance of its launch to market now anticipated for September 2017.
“As someone who endured a long and costly fertility journey (emotional, physical and financial), I’m optimistic about any non-invasive option that can help address fertility related issues and do so much earlier in the journey,” said Kim Whittemore, a recognized women’s sexual health advocate and M Pharmaceutical Board Member. “The science behind ToConceive is sound and will help many couples avoid more expensive and invasive treatments.”
“Anstice is proud to partner with M Pharmaceuticals as it introduces ToConceive to the market,” said Sheenah Rogers, Founder and CEO of Antsice Communications. “We will be working closely with M Pharma to implement an effective brand strategy and build strong awareness of this innovative new product among consumers.”
Over 9 million North American couples are struggling to create the family of their dreams (significantly more worldwide). For many of these couples, the search for success through Artificial Reproductive Therapy (ART) can be financially burdensome and emotionally taxing. The “necessity” of these procedures is a source of much debate, but to date, alternative therapies have been limited.
The science behind ToConceive is basedon the 2010 Nobel Prize in Medicine for In-Vitro Fertilization and Sperm Capacitation.The formulation was originally developed in Cincinnati, Ohio by an award-winning surgeon, OB-GYN and fertility expert. Unlike other over-the-counter lubrications, some of which contain spermicide, ToConceive is a vaginal gel, lubricant and moisturizer, clinically shown to help increase a woman’s own natural conception lubrication, called transudate, which helps aid in conception.
About M Pharmaceutical
Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for obesity, weight management and Female Health & Wellness. In addition to its recent acquisitions of C-103, a reformulation of Orlistat and assets from 40J’s LLC, the Company is scheduled to launch their FDA cleared fertility product branded as ToConceive in September of 2017.
M Pharmaceutical Inc. trades on the Canadian Securities Exchange (CSE) under the ticker symbol “MQ” as well as on the OTCQB as “MPHMF” and FWB (Frankfurt Stock Exchange) as “T3F2.”
For more information contact:
M Pharma Investor Relations
Phone: +1 (859) 868-3131
Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval, commercialization of the rights to the Company’s biomedical & drug technologies, and acquisition of new products. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com and the Company’s filings to the CSE at www.cnsx.ca. Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.
Notice regarding investigational devices: C-103 and Extrinsa are investigational drugs or devices and are not currently available outside of approved clinical trials. Claims regarding the safety and efficacy of these devices have not been evaluated by Health Canada, the U.S. Food and Drug Administration, or any other international regulatory body.